185 related articles for article (PubMed ID: 25553462)
21. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
Chen Q; Xie W; Kuhn DJ; Voorhees PM; Lopez-Girona A; Mendy D; Corral LG; Krenitsky VP; Xu W; Moutouh-de Parseval L; Webb DR; Mercurio F; Nakayama KI; Nakayama K; Orlowski RZ
Blood; 2008 May; 111(9):4690-9. PubMed ID: 18305219
[TBL] [Abstract][Full Text] [Related]
22. Regulation of Skp2 expression and activity and its role in cancer progression.
Chan CH; Lee SW; Wang J; Lin HK
ScientificWorldJournal; 2010 Jun; 10():1001-15. PubMed ID: 20526532
[TBL] [Abstract][Full Text] [Related]
23. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation.
Li X; Pham V; Tippin M; Fu D; Rendon R; Song L; Uchio E; Hoang BH; Zi X
Cell Commun Signal; 2019 Mar; 17(1):25. PubMed ID: 30885218
[TBL] [Abstract][Full Text] [Related]
24. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
25. Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation.
Kudo Y; Kitajima S; Ogawa I; Kitagawa M; Miyauchi M; Takata T
Mol Cancer Ther; 2005 Mar; 4(3):471-6. PubMed ID: 15767556
[TBL] [Abstract][Full Text] [Related]
26. p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Zhao H; Lu Z; Bauzon F; Fu H; Cui J; Locker J; Zhu L
Oncogene; 2017 Jan; 36(1):60-70. PubMed ID: 27181203
[TBL] [Abstract][Full Text] [Related]
27. E3 ligase SCF
Thacker G; Mishra M; Sharma A; Singh AK; Sanyal S; Trivedi AK
Life Sci; 2020 Sep; 257():118041. PubMed ID: 32622945
[TBL] [Abstract][Full Text] [Related]
28. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.
Li B; Lu W; Yang Q; Yu X; Matusik RJ; Chen Z
Prostate; 2014 Apr; 74(4):421-32. PubMed ID: 24347472
[TBL] [Abstract][Full Text] [Related]
29. Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
He DH; Chen YF; Zhou YL; Zhang SB; Hong M; Yu X; Wei SF; Fan XZ; Li SY; Wang Q; Lu Y; Liu YQ
Cancer Sci; 2021 Aug; 112(8):3218-3232. PubMed ID: 34080260
[TBL] [Abstract][Full Text] [Related]
30. Skp2-mediated p27(Kip1) degradation during S/G2 phase progression of adipocyte hyperplasia.
Auld CA; Fernandes KM; Morrison RF
J Cell Physiol; 2007 Apr; 211(1):101-11. PubMed ID: 17096381
[TBL] [Abstract][Full Text] [Related]
31. Skp2 stabilizes Mcl-1 and confers radioresistance in colorectal cancer.
Yu X; Zhou L; Liu W; Liu L; Gao F; Li W; Liu H
Cell Death Dis; 2022 Mar; 13(3):249. PubMed ID: 35301297
[TBL] [Abstract][Full Text] [Related]
32. Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent.
Wei S; Chu PC; Chuang HC; Hung WC; Kulp SK; Chen CS
PLoS One; 2012; 7(10):e47298. PubMed ID: 23071779
[TBL] [Abstract][Full Text] [Related]
33. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.
Lu W; Liu S; Li B; Xie Y; Adhiambo C; Yang Q; Ballard BR; Nakayama KI; Matusik RJ; Chen Z
Oncotarget; 2015 Jan; 6(2):771-88. PubMed ID: 25596733
[TBL] [Abstract][Full Text] [Related]
34. USP2 is an SKP2 deubiquitylase that stabilizes both SKP2 and its substrates.
Zhang F; Zhao Y; Sun Y
J Biol Chem; 2021 Oct; 297(4):101109. PubMed ID: 34425107
[TBL] [Abstract][Full Text] [Related]
35. Regulation of Skp2-p27 axis by the Cdh1/anaphase-promoting complex pathway in colorectal tumorigenesis.
Fujita T; Liu W; Doihara H; Wan Y
Am J Pathol; 2008 Jul; 173(1):217-28. PubMed ID: 18535175
[TBL] [Abstract][Full Text] [Related]
36. SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Li Z; Huang J; Yuan H; Chen Z; Luo Q; Lu S
Oncotarget; 2016 Apr; 7(14):18927-39. PubMed ID: 26942878
[TBL] [Abstract][Full Text] [Related]
37. Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2.
Ungermannova D; Gao Y; Liu X
J Biol Chem; 2005 Aug; 280(34):30301-9. PubMed ID: 15980415
[TBL] [Abstract][Full Text] [Related]
38. Skp2 regulates G2/M progression in a p53-dependent manner.
Hu R; Aplin AE
Mol Biol Cell; 2008 Nov; 19(11):4602-10. PubMed ID: 18716061
[TBL] [Abstract][Full Text] [Related]
39. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Old JB; Kratzat S; Hoellein A; Graf S; Nilsson JA; Nilsson L; Nakayama KI; Peschel C; Cleveland JL; Keller UB
Mol Cancer Res; 2010 Mar; 8(3):353-62. PubMed ID: 20197382
[TBL] [Abstract][Full Text] [Related]
40. Skp2 is necessary for Myc-induced keratinocyte proliferation but dispensable for Myc oncogenic activity in the oral epithelium.
Sistrunk C; Macias E; Nakayama K; Kim Y; Rodriguez-Puebla ML
Am J Pathol; 2011 Jun; 178(6):2470-7. PubMed ID: 21641375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
